Is IMRX or INM more undervalued in 2026?

CirclFi compares Immuneering Corporation (IMRX) and InMed Pharmaceuticals Inc. (INM) using 13 institutional-grade valuation models. IMRX has a Quality of Company score of 4.5/10 while INM scores 5.0/10.

Which is a better buy — IMRX or INM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IMRX and INM valuations compare?

IMRX at $5.77 and INM at $1.57 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IMRX vs INM Valuation Comparison 2026 — Intrinsic Value Analysis

IMRX

Pharmaceutical Preparations

Immuneering Corporation

Quality

4.5

out of 10

Value Trap

LOW

Price

$5.77

Last close

Models

7/13

Active

INM

Pharmaceutical Preparations

InMed Pharmaceuticals Inc.

Quality

5.0

out of 10

Value Trap

SAFE

Price

$1.57

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	IMRX Fair Value	IMRX Upside	INM Fair Value	INM Upside
Bayesian DCF	Intrinsic	$1.71	-70.4%	$1.18	-24.6%
Earnings Power Value	Intrinsic	—	—	$3.95	+452.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.67	-71.1%	$0.25	-64.7%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMRX vs INM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMRX vs INM — Which Stock Is More Undervalued?

INM scores higher with a 5.0/10 quality rating vs IMRX's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immuneering Corporation (IMRX) and InMed Pharmaceuticals Inc. (INM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMRX currently trades at $5.77 with a QOC of 4.5/10, while INM trades at $1.57 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).